Details about Rosalie Viney

Access statistics for papers by Rosalie Viney.

Last updated 2022-02-10. Update your information in the RePEc Author Service.

Short-id: pvi117

Working Papers

2015

1. Complexity and doctor choices when discussing contraceptives
   Health, Econometrics and Data Group (HEDG) Working Papers, HEDG, c/o Department of Economics, University of York View citations (1)

2012

2. Deriving utility weights for the EQ-5D-5L using a discrete choice experiment. CHERE Working Paper 2012/01
   Working Papers, CHERE, University of Technology, Sydney

2010

3. Evaluation of participants' experiences with a non-restrictive minimally-structured lifestyle intervention. CHERE Working Paper 2010/11
   Working Papers, CHERE, University of Technology, Sydney
4. General Practitioners knowledge, views and practices regarding cervical cancer screening in Australia. CHERE Working Paper 2010/6
   Working Papers, CHERE, University of Technology, Sydney
5. Reducing the use of ineffective health care interventions. CHERE Working Paper 2010/5
   Working Papers, CHERE, University of Technology, Sydney View citations (1)

2009

6. Evaluating changes in women's attitudes towards cervical screening following a screening promotion campaign and a free vaccination program. CHERE Working Paper 2009/3
   Working Papers, CHERE, University of Technology, Sydney

2008

7. A model for best practice HTA
   Working Papers, CHERE, University of Technology, Sydney
8. The effect of discounting on quality of life valuation using the Time Trade-Off, CHERE Working Paper 2008/3
   Working Papers, CHERE, University of Technology, Sydney

2007

9. Decisions about Pap tests: What influences women and providers?
   Working Papers, CHERE, University of Technology, Sydney View citations (1)
   See also Journal Article Decisions about Pap tests: What influences women and providers?, Social Science & Medicine, Elsevier (2009) View citations (14) (2009)
10. Incorporating economic evidence into cancer care: searching for the missing link
    Working Papers, CHERE, University of Technology, Sydney View citations (1)
11. Patients? perceptions of the value of PET in diagnosis and management of non-small call lung cancer, CHERE Working Paper 2007/5
    Working Papers, CHERE, University of Technology, Sydney
12. Validity, reliability and responsiveness of the EORTC QLQ-C30 and the EORTC QLQ-LC13 in Australians with early stage non-small cell lung cancer, CHERE Working Paper 2007/13
    Working Papers, CHERE, University of Technology, Sydney View citations (1)
13. Valuing EQ-5D health states: A review and analysis, CHERE Working Paper 2007/9
    Working Papers, CHERE, University of Technology, Sydney View citations (11)

2006

14. Catastrophic insurance: Impact of the Australian Medicare Safety Net on fees, service use and out-of-pocket costs, CHERE Working Paper 2006/9
    Working Papers, CHERE, University of Technology, Sydney View citations (2)
15. Does the reason for buying health insurance influence behaviour? CHERE Working Paper 2006/1
    Working Papers, CHERE, University of Technology, Sydney View citations (6)
16. Health care policy evaluation: empirical analysis of the restrictions implied by Quality Adjusted Life Years, CHERE Working Paper 2006/10
    Working Papers, CHERE, University of Technology, Sydney View citations (1)
17. Men?s preferences for treatment of early stage prostate cancer: Results from a discrete choice experiment, CHERE Working Paper 2006/14
    Working Papers, CHERE, University of Technology, Sydney
18. Who?s getting caught? An analysis of the Australian Medicare Safety Net, CHERE Working Paper 2006/8
    Working Papers, CHERE, University of Technology, Sydney View citations (1)

2004

19. An economic evaluation of the prison methadone program in New South Wales, CHERE Project Report No 22
    Research Reports, CHERE, University of Technology, Sydney
20. Why worry about awareness in choice problems? Econometric analysis of screening for cervical cancer
    Econometric Society 2004 Australasian Meetings, Econometric Society View citations (1)
    See also Journal Article Why worry about awareness in choice problems? Econometric analysis of screening for cervical cancer, Health Economics, John Wiley & Sons, Ltd. (2006) View citations (19) (2006)

2002

21. Review of Positron Emission Tomography at Royal Prince Alfred Hospital, CHERE Project Report No 18
    Research Reports, CHERE, University of Technology, Sydney
22. Using qualitative methods to validate a stated preference survey for evaluating health services, CHERE Discussion Paper No 47
    Discussion Papers, CHERE, University of Technology, Sydney View citations (1)

2001

23. Hospital in the Home in NSW, CHERE Project Report No 16
    Research Reports, CHERE, University of Technology, Sydney

2000

24. NSW breast and cervical screening program review, CHERE Project Report No 14
    Research Reports, CHERE, University of Technology, Sydney View citations (1)
25. Service impact analysis of telehealth in NSW, CHERE Project Report No 12
    Research Reports, CHERE, University of Technology, Sydney

1999

26. Consultancy to progress hospital in the home care provision: Final report, CHERE Project Report No 13
    Research Reports, CHERE, University of Technology, Sydney View citations (1)

1997

27. Linking health outcomes to priority setting, planning and resource allocation - Report to the NSW Department of Health, CHERE Project Report No 1
    Research Reports, CHERE, University of Technology, Sydney View citations (4)

1996

28. Delivery of less urgent ambulatory care in a hospital setting - Report the NSW Department of Health, CHERE Project Report No 2
    Research Reports, CHERE, University of Technology, Sydney

Journal Articles

2022

1. How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents
   PharmacoEconomics, 2022, 40, (2), 157-182

2021

2. Employer survey to estimate the productivity friction period
   The European Journal of Health Economics, 2021, 22, (2), 255-266
3. Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment
   PharmacoEconomics, 2021, 39, (9), 1085-1098 View citations (3)
4. Exploring the Trade-Off Between Economic and Health Outcomes During a Pandemic: A Discrete Choice Experiment of Lockdown Policies in Australia
   The Patient: Patient-Centered Outcomes Research, 2021, 14, (3), 359-371 View citations (4)
5. French Value-Set of the QLU-C10D, a Cancer-Specific Utility Measure Derived from the QLQ-C30
   Applied Health Economics and Health Policy, 2021, 19, (2), 191-202 View citations (1)
6. Investigating the Association Between Self-Reported Comorbid Anxiety and Depression and Health Service Use in Cancer Survivors
   PharmacoEconomics, 2021, 39, (6), 681-690
7. United States Utility Algorithm for the EORTC QLU-C10D, a Multiattribute Utility Instrument Based on a Cancer-Specific Quality-of-Life Instrument
   Medical Decision Making, 2021, 41, (4), 485-501 View citations (7)

2020

8. Birth models of care and intervention rates: The impact of birth centres
   Health Policy, 2020, 124, (12), 1395-1402
9. The SF-6Dv2: How Does the New Classification System Impact the Distribution of Responses Compared with the Original SF-6D?
   PharmacoEconomics, 2020, 38, (12), 1283-1288

2019

10. A systematic review of scabies transmission models and data to evaluate the cost-effectiveness of scabies interventions
    PLOS Neglected Tropical Diseases, 2019, 13, (3), 1-18 View citations (1)
11. Investigating the relative value of health and social care related quality of life using a discrete choice experiment
    Social Science & Medicine, 2019, 233, (C), 28-37 View citations (5)
12. One Method, Many Methodological Choices: A Structured Review of Discrete-Choice Experiments for Health State Valuation
    PharmacoEconomics, 2019, 37, (1), 29-43 View citations (8)
13. U.K. utility weights for the EORTC QLU‐C10D
    Health Economics, 2019, 28, (12), 1385-1401
14. Using Discrete-Choice Experiment Methods to Estimate the Value of Informal Care: The Case of Children with Intellectual Disability
    PharmacoEconomics, 2019, 37, (4), 501-511

2018

15. Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30
    PharmacoEconomics, 2018, 36, (2), 225-238 View citations (5)
16. How Should Discrete Choice Experiments with Duration Choice Sets Be Presented for the Valuation of Health States?
    Medical Decision Making, 2018, 38, (3), 306-318 View citations (2)

2017

17. Consideration Sets and Their Role in Modelling Doctor Recommendations About Contraceptives
    Health Economics, 2017, 26, (1), 54-73 View citations (5)
18. Is Dimension Order Important when Valuing Health States Using Discrete Choice Experiments Including Duration?
    PharmacoEconomics, 2017, 35, (4), 439-451 View citations (3)
19. Valuing Meta-Health Effects for Use in Economic Evaluations to Inform Reimbursement Decisions: A Review of the Evidence
    PharmacoEconomics, 2017, 35, (3), 347-362

2016

20. Costing Alternative Birth Settings for Women at Low Risk of Complications: A Systematic Review
    PLOS ONE, 2016, 11, (2), 1-17 View citations (3)
21. Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer
    PharmacoEconomics, 2016, 34, (10), 1039-1050 View citations (1)
22. Response Patterns in Health State Valuation Using Endogenous Attribute Attendance and Latent Class Analysis
    Health Economics, 2016, 25, (2), 212-224 View citations (8)
23. The Impact of Different DCE-Based Approaches When Anchoring Utility Scores
    PharmacoEconomics, 2016, 34, (8), 805-814 View citations (7)

2015

24. A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)
    PharmacoEconomics, 2015, 33, (8), 867-877 View citations (6)
25. Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review
    PharmacoEconomics, 2015, 33, (9), 905-924 View citations (14)

2014

26. AN AUSTRALIAN DISCRETE CHOICE EXPERIMENT TO VALUE EQ‐5D HEALTH STATES
    Health Economics, 2014, 23, (6), 729-742 View citations (26)
27. ESTIMATING HEALTH STATE UTILITY VALUES FROM DISCRETE CHOICE EXPERIMENTS—A QALY SPACE MODEL APPROACH
    Health Economics, 2014, 23, (9), 1098-1114 View citations (4)
28. Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique
    The European Journal of Health Economics, 2014, 15, (1), 93-112 View citations (2)
29. Valuing SF-6D Health States Using a Discrete Choice Experiment
    Medical Decision Making, 2014, 34, (6), 773-786 View citations (7)

2013

30. A Pilot Discrete Choice Experiment to Explore Preferences for EQ-5D-5L Health States
    Applied Health Economics and Health Policy, 2013, 11, (3), 287-298 View citations (33)
31. Are the True Impacts of Adverse Events Considered in Economic Models of Antineoplastic Drugs? A Systematic Review
    Applied Health Economics and Health Policy, 2013, 11, (6), 619-637
32. EFFICIENCY AND EQUITY: A STATED PREFERENCE APPROACH
    Health Economics, 2013, 22, (5), 568-581 View citations (16)
33. The effect of adverse information and positive promotion on women's preferences for prescribed contraceptive products
    Social Science & Medicine, 2013, 83, (C), 70-80 View citations (5)
34. Using repeated choice experiments to evaluate the impact of policy changes on cervical screening
    Applied Economics, 2013, 45, (14), 1845-1855 View citations (3)

2012

35. What’s Good and Bad About Contraceptive Products?
    PharmacoEconomics, 2012, 30, (12), 1187-1202
    Also in PharmacoEconomics, 2012, 30, (12), 1187-1202 (2012) View citations (1)

2011

36. Preferences for new and existing contraceptive products
    Health Economics, 2011, 20, (S1), 35-52 View citations (27)

2009

37. Decisions about Pap tests: What influences women and providers?
    Social Science & Medicine, 2009, 68, (10), 1766-1774 View citations (14)
    See also Working Paper Decisions about Pap tests: What influences women and providers?, Working Papers (2007) View citations (1) (2007)
38. Who's Getting Caught? An Analysis of the Australian Medicare Safety Net
    Australian Economic Review, 2009, 42, (2), 143-154 View citations (12)

2007

39. Economic Evidence at the Local Level
    PharmacoEconomics, 2007, 25, (12), 1055-1062 View citations (2)

2006

40. Why worry about awareness in choice problems? Econometric analysis of screening for cervical cancer
    Health Economics, 2006, 15, (1), 33-47 View citations (19)
    See also Working Paper Why worry about awareness in choice problems? Econometric analysis of screening for cervical cancer, Econometric Society 2004 Australasian Meetings (2004) View citations (1) (2004)

2005

41. Empirical investigation of experimental design properties of discrete choice experiments in health care
    Health Economics, 2005, 14, (4), 349-362 View citations (42)

2004

42. Using stated preference discrete choice modeling to evaluate health care programs
    Journal of Business Research, 2004, 57, (9), 1026-1032 View citations (42)

2002

43. Using stated preference discrete choice modelling to evaluate the introduction of varicella vaccination
    Health Economics, 2002, 11, (5), 457-465 View citations (36)

2001

44. Using programme budgeting and marginal analysis to assist population based strategic planning for coronary heart disease
    Health Policy, 2001, 55, (3), 173-186 View citations (8)

1999

45. Carrots and sticks—the fall and fall of private health insurance in Australia
    Health Economics, 1999, 8, (8), 653-660 View citations (24)

1998

46. Linking measures of health gain to explicit priority setting by an Area Health Service in Australia
    Social Science & Medicine, 1998, 47, (12), 2067-2074

1991

47. Sex Discrimination and Non-random Sampling in the Australian Labour Market
    Australian Economic Papers, 1991, 30, (56), 28-49 View citations (8)

Chapters

2012

1. Design of Choice Experiments in Health Economics
   Chapter 42 in The Elgar Companion to Health Economics, Second Edition, 2012 View citations (2)
   Also in Chapter 39 in The Elgar Companion to Health Economics, 2006 (2006) View citations (1)